GRDX

3.1608.41%
JA

Jack A. Syage

Independent Director

Dr. Jack A. Syage, PhD, is Independent Director of GridAI Technologies Corp. (formerly known as Entero Therapeutics) since March 2024. He serves as Director of Entero Therapeutics, Inc. (formerly known as First Wave BioPharma, Inc.) since March 13, 2024 and served as its President and Chief Scientific until August 2024 and served as its Chief Executive Officer and served as its Chief Operations Officer. He co-founded ImmunogenX, LLC in 2013 and serves as its Chief Executive Officer. Dr. Syage founded Syagen Technology Inc. in 1996 and served as its Chief Executive Officer and President. His honorary positions include member of the Editorial Advisory Board of the Journal of Physical Chemistry from 1996 to 2000, invited participant at the Nobel Symposium in Chemistry (1996), Visiting Professor at the University of California, Irvine from 1999 to 2004, Visiting Professor at the Université de Paris-Sud, Orsay France since 1995, Plenary Lecturer at the Okazaki Conference since 1996 and Chairman of a DOE Committee that established a National Environmental Facility since 1992. Dr. Syage serves as a Director of Syagen Technology Inc. He served as Director of Flamentera AG, Advanced Telesensors and Appellation Ventures. He has published over 120 papers and delivered over 50 invited talks in fields of mass spectrometry, trace detection and ultrafast spectroscopy and has 14 U.S. patents issued or pending. Dr. Syage received a BA in Chemistry from Hamilton College (1976) and a Ph.D. in Physical Chemistry from Brown University in 1982 and received several academic awards including the Best Thesis Prize. He was a postdoctoral fellow at Caltech under a Nobel Laureate from 1982 to 1984.

Positions